SCHEDULE: KKR Exits BridgeBio Stake After Share Sale

KKR entities have completed the sale of 5 million shares of BridgeBio Pharma, Inc. common stock, reducing their beneficial ownership to below 5% and marking an exit filing.

Summary

• KKR Genetic Disorder L.P. sold 5,000,000 shares of BridgeBio Pharma, Inc. common stock.
• The sale occurred on August 13, 2026, with the offering closing on August 17, 2026.
• The net price per share to KKR Genetic Disorder L.P. was $77.415.
• Following the sale, KKR entities no longer beneficially own more than 5% of BridgeBio Pharma's common stock.
• This filing serves as an exit filing for KKR's significant stake.
• An investment vehicle managed by an indirect subsidiary of KKR Group Partnership L.P. also purchased 133,900 shares of preferred stock on July 1, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing, primarily an exit filing after a significant sale of shares, indicating a reduction in stake rather than a new strategic move.

Positives

• Successful sale of a large block of shares at a defined price ($77.415 per share).
• Completion of the offering and subsequent exit from a >5% ownership position.

Negatives

• Significant reduction in KKR's stake in BridgeBio Pharma, potentially signaling a change in investment strategy or conviction.
• The sale of 5 million shares represents a substantial divestment.

Risks

• The filing does not explicitly mention any new risks, but the exit of a major shareholder like KKR could be interpreted by the market as a negative signal regarding future prospects.
• The lock-up agreement restricts further disposal of shares for 30 days post-prospectus supplement, but this is a standard condition for such offerings.

Future Outlook

The filing primarily concerns a past transaction (share sale) and serves as an exit filing. It does not contain specific forward-looking statements or guidance from BridgeBio Pharma, Inc. itself, but rather details the completion of a stock offering by a selling stockholder.

Management Comments

• This Amendment No. 7 serves as an exit filing by the Reporting Persons, as they ceased to be the beneficial owners of more than five percent of the Common Stock on August 17, 2026.
• The Reporting Persons may be deemed to have but disclaim beneficial ownership over the securities held by an Alternative Vehicle.
• The filing of this Schedule 13D shall not be construed as an admission that any of the above-listed entities or individuals is the beneficial owner of any securities covered by this Schedule 13D for purposes of Section 13(d) or Section 13(g) or for any other purposes.

Industry Context

StockSavvy.ai notes that this filing reflects a common activity for private equity firms like KKR, which often invest in public companies and then exit their positions through secondary offerings or block trades. The sale of a significant stake by a major investor can sometimes be interpreted by the market as a signal, though in this case, it's framed as an exit from a >5% position.

Comparison to Industry Standards

• The sale of 5 million shares at $77.415 per share is a substantial secondary offering, typical for large institutional investors exiting positions.
• The use of a shelf registration statement (Form S-3ASR) and a prospectus supplement is standard practice for such offerings.
• The lock-up period of 30 days is also a common term in underwriting agreements for secondary offerings to stabilize the stock price post-offering.

Related Party Transactions

• An investment vehicle managed by an indirect subsidiary of KKR Group Partnership L.P. purchased 133,900 shares of BridgeBio Pharma's Series A Cumulative Convertible Participating Preferred Stock for $1,000 per share on July 1, 2026.

Stakeholder Impact

• Shareholders: The sale of a large block of shares by a major investor could lead to short-term price pressure, although the offering was structured to mitigate this. The exit may also be interpreted as a lack of further conviction by KKR.
• Creditors: No direct impact mentioned.
• Employees: No direct impact mentioned.
• Suppliers/Customers: No direct impact mentioned.

Next Steps

• KKR entities have completed their exit from a beneficial ownership stake exceeding 5% in BridgeBio Pharma, Inc.
• The lock-up agreement restricts further disposal of shares for 30 days after the final prospectus supplement date.

Key Dates

Recommendation

The filing primarily details an exit by KKR, reducing their stake below 5%. While the sale itself is a significant event, it doesn't provide new operational or financial data about BridgeBio Pharma's core business. The price of $77.415 per share provides a reference point, but without further context on BridgeBio's performance or outlook, a 'hold' recommendation is prudent, awaiting more substantive company updates.

Keywords

BridgeBio Pharma, KKR, Schedule 13D, Share Sale, Underwriting Agreement, Exit Filing, Common Stock, KKR Genetic Disorder L.P.